Medtronic (NYSE:MDT) announced today that it entered into a set of agreements to acquire insulin delivery technology developer EOFlow. Seongnam, South Korea-based EOFlow develops the EOPatch — a tubeless, wearable and fully disposable insulin delivery device. EOFlow already launched its EOPatch insulin delivery system in Korea and Europe. The company submitted the insulin delivery device […]
Mergers & Acquisitions
Bigfoot Biomedical acquires insulin titration algorithm developed at McGill University
Bigfoot Biomedical announced today that it acquired a reinforcement learning algorithm for insulin titration from McGill University. Developers at McGill designed the algorithm to observe how well people with insulin-requiring diabetes respond to a particular dose. It provides a recommended adjustment based on the body’s response. Milpitas, California-based Bigfoot said the developers built the algorithm […]
Insulet acquires assets of Automated Glucose Control for $25M
Insulet (Nasdaq:PODD) announced today that it acquired the assets of Automated Glucose Control, a developer of insulin delivery technology. This marks the second asset buy in as many days for Insulet. Yesterday, the company picked up automated insulin delivery patents from Bigfoot Biomedical. Both acquisitions cost the company $25 million. Palo Alto, California-based Automated Glucose Control […]
Insulet acquires insulin pump patents from Bigfoot Biomedical for $25M
Insulet (Nasdaq:PODD) announced today that it acquired assets related to Bigfoot Biomedical’s pump-based automated insulin delivery technologies. Acton, Massachusetts-based Insulet paid $25 million to acquire the AID assets. These include certain Bigfoot patents related to pumps that may be used for AID therapy. Insulet already develops its own AID technology with its Omnipod platform. The […]
The year ahead in diabetes care: what to expect in 2023
After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023. Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more. You can read all about the biggest diabetes stories […]
Tandem Diabetes Care completes acquisition of insulin pump maker AMF Medical
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it completed its previously announced acquisition of AMF Medical. San Diego-based Tandem announced plans to acquire the maker of the Sigi patch pump for insulin delivery last month. Switzerland-based AMF Medical does not offer Sigi commercially. The system received FDA breakthrough device designation just over one year ago. The […]
Ypsomed, Mediq complete sale of DiaExpert
Ypsomed and Mediq announced today that they completed the sale of mail-order retailer for diabetes care DiaExpert. Germany-based DiaExpert specializes in insulin pump therapy. The companies previously announced the sale of DiaExpert in October. This sale allows Ypsomed to focus on the manufacture and sale of its own medical technologies. That focus continues to narrow […]
Tandem Diabetes Care to acquire patch pump maker AMF Medical
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it acquired AMF Medical, maker of the Sigi patch pump for insulin delivery. Switzerland-based AMF Medical currently develops the Sigi patch pump and does not offer it commercially. The system received FDA breakthrough device designation just over one year ago. AMF Medical designed Sigi as an ergonomic, rechargeable […]
Boston Scientific to acquire majority stake in interventional tech developer Acotec
Boston Scientific (NYSE:BSX) announced that it intends to make a partial offer to acquire a majority stake in Acotec. Marlborough, Massachusetts-based Boston Scientific’s offer could add up to a maximum of 65% of Acotec’s shares. Its proposed price totals HK$20 per share. That amounts to approximately $523 million for the 65% stake at current exchange […]
TriSalus releases positive data for its catheter-based drug delivery tech
TriSalus Life Sciences today announced positive clinical results for its Pressure-Enabled Regional Immuno-Oncology technology. The company, currently in the process of going public through a SPAC merger, filed a presentation for investors. It features information regarding its ongoing PERIO 01 and PERIO 02 clinical studies. The studies evaluate the TriNav pressure-enabled drug delivery technology for […]
